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Background
Pre-eclampsia is part of a spectrum of conditions known as the hypertensive (high blood pressure) disorders of pregnancy and is defined as hypertension and proteinuria detected for the first time in the second half of pregnancy (after 20 weeks' gestation). Pre-eclampsia complicates 2-8% of pregnancies and may have serious effects on mother and child, which makes it an important threat to public health in both developed and developing countries. Once women are identified to be at high risk, they can be targeted for more intensive antenatal surveillance and prophylactic interventions. This report contains a health technology assessment of current strategies for risk stratification and prevention to guide clinical practice and future research in this field.
Objectives
The aim of the project was to identify combinations of test and treatments that would predict and help prevent pre-eclampsia. This study completed three distinct pieces of work to contribute to this goal:
• a series of systematic reviews on the accuracy of tests for the prediction of pre-eclampsia • a series of systematic reviews of effectiveness of interventions with potential to reduce the number of cases of pre-eclampsia • a health economic evaluation, including an economic model, of the combined effect of tests and interventions and their cost-effectiveness.
Methods
Protocols were developed for test accuracy and effectiveness systematic reviews which used up-todate review methods, including searches without language restrictions, study quality assessment and meta-analysis where appropriate. Although there was a slight variation between the search end-date of different systematic reviews, searches were generally conducted to 
Results

Main findings of test accuracy reviews
There were 27 tests reviewed [body mass index (BMI), ␣-foetoprotein, cellular and total fibronectin, foetal DNA, haemoglobin, haematocrit, human chorionic gonadotrophin, oestriol, uric acid, urinary calcium excretion, urinary calcium/creatinine ratio, several forms of proteinuria/albuminuria and several flow velocity waveforms of Doppler uterine artery]. The quality of studies and the accuracy of tests were generally poor. Some tests appeared to have high specificity, but at the expense of compromised sensitivity. Only a few tests reached specificities above 90%. These were BMI > 34, ␣-foetoprotein and uterine artery Doppler (bilateral notching). The only Doppler test with a sensitivity of over 60% was resistance index and combinations of indices. Kallikreinuria had a sensitivity of over 80%. Cellular and total fibronectin and kallikreinuria were found to have specificities above 90%. However, these estimates were based on single studies. Also, a few tests not commonly found in routine practice, such as kallikreinuria and sodium dodecyl sulfate polyacrylamide gel electrophoresis proteinuria, seemed to offer the promise of high sensitivity, without compromising specificity, but these too would require further investigation.
Main findings of effectiveness reviews
Sixteen systematic reviews of interventions are presented in this report, of which 15 provided estimates of effectiveness in preventing preeclampsia. The quality of included studies was variable; many reviews included only small, poorquality trials and a small number of reviews included large, well-designed trials. The largest review was of antiplatelet agents, primarily lowdose aspirin, and included 51 trials (36,500 women). This was the only review where the intervention was shown to prevent both preeclampsia [RR 0.81, 95% confidence interval (CI) 0.75 to 0.88] and its consequences for the baby (death, preterm birth and small for gestational age). Calcium supplementation also reduced the risk of pre-eclampsia (12 trials, 15,206 women, RR 0.48, 95% CI 0.33 to 0.69) but with some uncertainty about the impact on outcomes for the baby. The only other intervention associated with a reduction in RR of pre-eclampsia was rest at home, with or without a nutritional supplement, for women with normal blood pressure. However, this review included just two small trials (106 women) and its results should be interpreted with caution. Although the review of antioxidant agents (vitamins C and E in particular) presented here reports a reduction in the relative risk of preeclampsia, two large trials have subsequently reported their results. In the recently updated Cochrane review, the effect on pre-eclampsia is no longer statistically significant.
Main findings from the economic evaluation
The cost of most of the tests was modest, ranging from £5 for blood tests such as serum uric acid to approximately £20 for Doppler tests. Similarly, the cost of most interventions was also modest. In contrast, the best estimate of additional average cost associated with an average case of preeclampsia was high at approximately £9000.
The results of the modelling revealed that prior testing with the test accuracy sensitivities and specificities identified appeared to offer little as a way of improving cost-effectiveness. Based on the evidence reviewed, none of the tests appeared sufficiently accurate to be clinically useful and the results of the model favoured no-test/treat-all strategies.
The treatments included in the main analysis were rest at home, antiplatelets, antioxidants and calcium as these were the interventions where the RRs and 95% CIs showed they were unlikely to be associated with a worse outcome of pre-eclampsia frequency. However, if the results of the updated Cochrane review on antioxidants had been available when the economic model was run, antioxidants would not have been so included.
Rest at home without any initial testing was the most cost-effective 'test-treatment' combination, delivering the greatest reduction in number of cases of pre-eclampsia at virtually zero additional cost (to the NHS). Calcium supplementation to all women, without any initial testing, was the second most cost-effective. The costs averted as a result of this reduction in cases of pre-eclampsia greatly exceed the cost of the calcium supplementation. Paradoxically, antiplatelet agents, the treatment about which there was greatest certainty of effectiveness, did not feature among the costeffective options highlighted. This was because the size of the effect on number of cases of preeclampsia prevented, on current evidence, was smaller than the effect of rest at home and calcium supplementation. Thus, the very low cost Health Technology Assessment 2008; Vol. 12: No. 6 (Executive summary) ᭤ associated with antiplatelet agents was outweighed by the higher number of pre-eclampsia cases and the high associated cost. Calcium was more costly compared with antiplatelets but had fewer cases of pre-eclampsia and was therefore shown to be relatively much more cost-effective by the economic model.
All three main predictions of the economic model were affected by uncertainty. However, effective treatments (RR <0.7) with modest costs (<£50) applied to all women without prior testing were likely to be preferred from the perspective of costeffectiveness. Threshold analyses conducted in the economic model suggested that tests with upper range costs would need substantially improved sensitivities (assuming best level of specificity achieved in any test was maintained). The economic model provided little support that any form of Doppler test has sufficiently high sensitivity and specificity to be cost-effective for the early identification of pre-eclampsia. The economic model also suggested that the pattern of cost-effectiveness was no different in high-risk mothers than the low-risk mothers considered in the base case.
Conclusions
None of the tests evaluated is sufficiently accurate, in our opinion, to suggest its routine use in clinical practice. Calcium and antiplatelet agents, primarily low-dose aspirin, are the interventions shown to prevent pre-eclampsia. The most costeffective approach to reducing pre-eclampsia is likely to be the provision of an effective, affordable and safe intervention applied to all mothers without prior testing to assess levels of risk. However, we believe that it is probably premature to suggest the implementation of a treat-all intervention strategy such as advice to rest or pharmacological interventions such as low-dose aspirin or calcium supplementation at present. However, the feasibility and acceptability to women of offering universal application of interventions could be explored. Some consideration needs to be given to whether the health service should continue to do certain tests whose main perceived value is to help identify preeclampsia when their usefulness is questionable.
Recommendations for further research
Rigorous evaluation is needed of tests with modest cost whose initial assessments suggest that they may have high levels of both sensitivity and specificity. Similarly, there is a need for highquality, adequately powered randomised controlled trials to investigate whether interventions such as advice to rest are indeed effective in reducing pre-eclampsia. In future, an economic model should be developed which considers not just pre-eclampsia, but other related outcomes, particularly those relevant to the infant such as perinatal death, preterm birth and small for gestational age. Such a modelling project should make provision for primary data collection on the safety of interventions and their associated costs.
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